Skip to Main Content

Paper Details

VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED.
Retina
8
2018
AFLIBERCEPT, Diabetic Retinopathy, Patients, RANIBIZUMAB, aflibercept, neovascular age-related macular degeneration, patients, ranibizumab
Aged, Aged, 80 and over, Angiogenesis Inhibitors, Choroidal Neovascularization, Drug Substitution, Female, Humans, Macular Degeneration, Male, Middle Aged, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Visual Acuity
Author NameAffiliation
Cecilia S LeeUniversity of Washington
Alisa KimUniversity of Washington
Douglas M BaughmanUniversity of Washington
Catherine EganThe NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust.
Catherine EganUCL Institute of Ophthalmology
Clare BaileyBristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust
Robert L JohnstonGloucestershire Hospitals NHS Foundation Trust
Salim NathaWigan and Leigh NHS Foundation Trust
Rehna KhanCalderdale and Huddersfield NHS Foundation Trust
Christopher BrandSheffield Teaching Hospitals NHS Foundation Trust
Toks AkereleHinchingbrooke Health Care NHS Trust
Martin McKibbinMid Yorkshire Hospitals NHS Trust.
Louise DowneyHull and East Yorkshire Hospitals NHS Trust
Sahar Al-HusainyHeart of England NHS Foundation Trust
Aaron LeeUniversity of Washington
Adnan TufailThe NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust.
Adnan TufailUCL Institute of Ophthalmology
  • 1 - 17

Datasets

Release 1.2